Send to

Choose Destination
Arch Dermatol. 2003 Jun;139(6):759-64.

308-nm excimer laser for the treatment of psoriasis: induration-based dosimetry.

Author information

Gange Photomedicine Research Center, Department of Dermatology, Harvard Medical School, Massachusetts General Hospital, Boston 02114, USA.



To determine the response of stubborn psoriatic plaques to the 308-nm excimer laser.


Controlled study with a before-after design.


A university-based clinical research center.


Adult subjects with recalcitrant plaque psoriasis that have not responded to other therapies for at least 2 months.


Selected psoriatic plaques were treated with the 308-nm excimer laser. One lesion was left as a control. Each plaque was treated 2 times a week, with an initial dose based solely on the induration component of the modified Psoriasis Area and Severity Index score for that lesion. Subsequent treatments were twice a week with dosage increments up to 50%, based on the change in induration. Four final consolidation doses were given once the induration score was reduced to zero.


Eighteen subjects were treated. There were 4 dropouts because of various scheduling problems. In the remaining 14 subjects, 44 plaques received a mean of 10 treatments (range, 4-14). Treatments were quick and well tolerated. The mean cumulative dose was 8.8 J/cm2 (range, 2.2-22.8 J/cm2). Compared with controls, treated plaques showed significant improvement (P<.001). The only adverse event was a mild sunburn-like reaction in 2 subjects after 1 treatment.


Selective targeting of laser-generated 308-nm excimer radiation with this convenient subblistering dosage schedule based on induration allows for individualized treatment plans for each plaque. Clearing of stubborn psoriatic lesions occurs rapidly and safely.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center